Penumbra (PEN) concentration risks

The company's concentration profile combines a high-share product focus and a high-share supply dependency, two exposures that are structurally interlinked. On the revenue side, the thrombectomy product category is the largest disclosed driver of the business — a high-share, structural concentration that reflects the company's deliberate specialization in this clinical area. Revenue of $947.9 million was generated from thrombectomy products for the year ended December 31, 2025, making the trajectory of that product category the dominant variable in the top line. On the input side, the company typically procures certain raw materials and components from a single or limited number of suppliers — a high-share dependency exposure. This is the more idiosyncratic of the two: a supply disruption at a sole-sourced component vendor could constrain production and affect revenue in ways that the company cannot easily offset through commercial action. The character here is dependency — reliance on specific suppliers who are not substitutable without lead time and qualification cost. The two exposures reinforce each other: if supply constraints arise in the components most critical to thrombectomy products, the impact is amplified by the revenue concentration in that single category. There is no disclosed geographic, customer, or additional product-line concentration that would further compound the picture, but the intersection of a single-product focus and a limited-supplier input base is the key risk axis to monitor.

For the engine’s reasoning on PEN’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.